Serotonergic and non-serotonergic targets in the pharmacotherapy of visceral hypersensitivity.
Visceral hypersensitivity is considered a key mechanism in the pathogenesis of functional gastrointestinal (GI) disorders. Targeting visceral hypersensitivity seems an attractive approach to the development of drugs for functional GI disorders. This review summarizes current knowledge on targets for the treatment of visceral hypersensitivity, and the status of current and future drug and probiotic treatment development, and the role of pharmacogenomic factors.
Bueno
L
L
Neurogastroenterology Unit INRA, Toulouse, France. lbueno@toulouse.inra.fr
de Ponti
F
F
Fried
M
M
Kullak-Ublick
G A
GA
Kwiatek
M A
MA
Pohl
D
D
Quigley
E M M
EM
Tack
J
J
Talley
N J
NJ
D000818:Animals; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use; D005767:Gastrointestinal Diseases / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology; D041981:Gastrointestinal Tract / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D017288:Pain Threshold / Q000187:drug effects*; D019936:Probiotics / Q000627:therapeutic use; D011985:Receptors, Serotonin / Q000187:drug effects; D012701:Serotonin / Q000378:metabolism*; D018490:Serotonin Agents / Q000627:therapeutic use; D012702:Serotonin Antagonists / Q000627:therapeutic use; D017833:Visceral Afferents / Q000187:drug effects*
D052246:Cyclooxygenase 2 Inhibitors; D011985:Receptors, Serotonin; D018490:Serotonin Agents; D012702:Serotonin Antagonists; D012701:Serotonin